Australia

TeamHive Launches Free Team Effectiveness Indicator, Giving Any Leader or Team Member Instant, Research-Backed Insight Into How Their Team Really Works

HR tech platform, validated by the University of Newcastle, makes its PLUS model diagnostic available at no cost to teams worldwide SYDNEY, April 21, 2026 /PRNewswire/ -- TeamHive (https://team-hive.co/ ), the evidence-based team effectiveness platform, today announced the...

2026-04-22 03:15 3061

Seeing Machines Releases Part 2 of Technical Paper Series on Intoxication

Driver Monitoring System technology enables real-time assessment of a driver's functional state relative to the driving environment CANBERRA, Australia, April 21, 2026 /PRNewswire/ -- Seeing Machines Limited, a global leader in vision-based monitoring technology, has released the second part of ...

2026-04-21 14:00 3833

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originat...

2026-04-15 20:00 6690

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...

2026-04-14 21:02 5684

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative c...

2026-04-02 19:00 6334

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...

2026-03-25 21:01 7113

Breaking the Design Barrier: X-Design Evolves into Zawa, Launching a Dedicated Creative AI Agent for Branding

From "democratizing design" to "systematizing growth," Zawa's new "Zero to Wow" philosophy redefines the future of visual automation for SMBs and local merchants. SYDNEY, March 18, 2026 /PRNewswire/ -- X-Design, the pioneering platform that made professional design accessible to everyone, today ...

2026-03-19 03:39 6305

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

HIGHLIGHTS * Oral presentation on key results from the Co-PSMA (NCT06907641 )[1] Investigator-Initiated Trial (IIT) was delivered by ProfLouise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the ...

2026-03-17 21:01 7701

Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer

LISMORE, Australia, March 15, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment f...

2026-03-16 09:43 4065

Vmake Video Enhancer Introduces "AI 4K+": Setting a New Standard in AI Video Enhancement

SYDNEY, March 10, 2026 /PRNewswire/ -- Vmake recently announced a major upgrade to VmakeVideo Enhancer , introducing AI 4K+, a new enhancement mode designed to deliver sharper, more natural-looking upscales for creators and businesses who need premium video qualit...

2026-03-11 01:00 6055

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...

2026-03-10 21:02 7772

Faybl launches in US, offering RIAs chance to shape the future of AI-powered advice

* Faybl delivers proven efficiency gains of up to 70 percent in support of US advice industry that is struggling for capacity * Faybl has grown Australian user base by 50 percent; already testing V2 in home market * Anthony Lipp announced as new Adviser * Faybl's leadership team will be at...

2026-03-10 20:00 5233

Westpac to change the format of its long-term USD funding

SYDNEY, March 5, 2026 /PRNewswire/ -- Westpac Banking Corporation ("Westpac") today announced its intention to voluntarily deregister from the United States Securities and Exchange Commission (the "SEC") by filing a Form 15F with the SEC as early asMay 2026. Upon filing the Form 15F, Westpac's re...

2026-03-06 01:59

Firmable Raises $14m Series A to Take AI-Native Sales Platform Global

MELBOURNE, Australia, March 2, 2026 /PRNewswire/ -- Firmable, Asia-Pacific's leading AI (artificial intelligence) sales platform, has raised$14 million in Series A funding led by Airtree, with participation from existing investors. The funding will support Firmable's expansion tothe United States...

2026-03-03 00:30 7710

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...

2026-02-27 04:34 9268

GTM.io Launches Operating Partner Model to Close the Go-to-Market Execution Gap

Built for scaling B2B technology companies seeking stronger pipeline, more consistent revenue execution and sustainable customer expansion. SYDNEY, Feb. 25, 2026 /PRNewswire/ -- GTM.io today announced the formal launch of its Operating Partner model, designed to address a persi...

2026-02-26 04:00 4724

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

2026-02-16 22:03 11412

Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...

2026-02-06 20:00 8273

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...

2026-01-30 21:00 11317

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....

2026-01-27 21:00 10385
123456 ... 40

Week's Top Stories